Radical Resection of Adult Low Grade Oligodendroglioma without Adjuvant Therapy: Results of a Prospective Treatment Protocol—Surgical Treatment of Low-Grade Oligodendroglioma

Donald A. Ross, Lynda Yang, Oren Sagher, Amy M. Ross

.

DOI: 10.4236/jct.2011.22030                

Abstract

The goal of this work was to demonstrate prospectively that maximal surgical resection of low grade oligodendrogliomas without adjuvant therapy does not reduce life expectancy over that of historical controls. All patients with surgically accessible grade II oligodendrogliomas underwent maximal resection using stereotactic guidance and/or cortical mapping and were followed with serial MRI scans without adjuvant therapy until either progression or spread into brain regions deemed not surgically resectable. Nineteen patients were treated between 1993 and 2006. Ten patients required reoperation an average of 55 months after their first surgery. Nine patients progressed to anaplastic tumors an average of 42 months after their first surgery: six patients died from their tumors an average of 73 months after diagnosis, two are still alive 76 and 18 months after progression, and one was lost to follow up. Ten patients are alive and progression-free an average of 116 months after diagnosis, one of whom was lost to follow up at 106 months from diagnosis. Four patients are alive and event-free an average of 125 months after diagnosis. All are male and three had tumors in the superior frontal gyrus. The event-free survival, progression-free survival, and overall survival of our patients are not worse than those of patients treated with postoperative adjuvant therapy. Withholding adjuvant therapy at diagnosis appears to be safe. It will be important to establish the molecular differences between the patients who did very well and those who progressed so that adjuvant therapy could be offered to the latter.

Keywords

Corticography, Craniotomy, Extent Of Resection, Oligodendroglioma

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	S. Chowdhary and M. C. Chamberlain, “Oligodendroglial tumors,” Expert Review of Neurotherapeutics, Vol. 6, No. 4, 2006, pp. 519-532. doi:10.1586/14737175.6.4.519
[2]	B. Devaux, B. Turak, T. Roujeau, P. Page, C. Cioloca, A. C. Ricci, P. Bret, F. Nataf and F. X. Roux, “Adult Supratentorial Oligodendrogliomas. Surgical Treatment: Indications and Techniques,” Neurochirurgie, Vol. 51, No. 3-4(Part 2), 2005, pp. 353-367.
[3]	H. H. Engelhard, “Current Diagnosis and Treatment of Oligodendroglioma,” Neurosurg Focus, 2002, p. 12:E2.
[4]	W. P. Mason, “Oligodendroglioma,” Current Treatment Options in Neurology, Vol. 7, No. 4, 2005, pp. 305-314. doi:10.1007/s11940-005-0040-0
[5]	G. Ozyigit, C. Onal, M. Gurkaynak, F. Soyiemezoglu and F. Zorlu, “Postoperative Radiotherapy and Chemotherapy in the Management of Oligodendroglioma: Single Institutional Review of 88 Patients,” Journal of Neuro-Oncology, Vol. 75, No. 2, 2005, pp. 189-193. doi:10.1007/s11060-005-2057-3
[6]	M. R. Rosenfeld, “Should Radiotherapy for Low-Grade Glioma be Given Immediately after Surgery or at the Time of Progression?” Nature Clinical Practice Neurology, Vol. 2, No. 3, 2006, pp. 128-129. doi:10.1038/ncpneuro0128
[7]	F. X. Roux and F. Nataf, “Cerebral Oligodendrogliomas in Adults and Children. Current Data and Perspectives,” Neurochirurgie, Vol. 51, No. 3-4(Pt 2), 2005, pp. 410-414.
[8]	J. Piepmeier, S. Christopher, D. Spencer, T. Byrne, J. Kim, J. P. Knisel, J. Lacy, L. Tsukerman and R. Makuch, “Variations in the Natural History and Survival of Patients with Supratentorial Low-Grade Astrocytomas,” Neurosurgery, Vol. 38, No. 5, 1996, pp. 872-878. doi:10.1097/00006123-199605000-00002
[9]	S. Puget and J. T. Rutka, “Malignant Brain Tumors: Two Steps Forward,” Clinical Neurosurg, Vol. 54, 2007, pp 4-9.
[10]	P. Kleihues, D. N. Louis, B. W. Scheithauer, L. B. Rorke, G. Reifenberger, P. C. Burger and W. K. Cavenee, “The WHO Classification of Tumors of the Nervous System,” Journal of Neuropathology & Experimental Neurology, Vol. 61, No. 3, 2002, pp. 215-225.
[11]	M. J. van den Bent, “Advances in the Biology and Treatment of Oligodendrogliomas,” Current Opinion in Neurology, Vol. 17, No. 6, 2004, pp. 675-680. doi:10.1097/00019052-200412000-00006
[12]	C. Walker, D. G. du Plessis, K. A. Joyce, D. Fildes, A. Gee, B. Haylock, D. Husband, T. Smith, J. Broome and P. C. Warnke, “Molecular Pathology and Clinical Characteristics of Oligodendroglial Neoplasms,” Annals of Neurology, Vol. 57, No. 6, 2005, pp. 855-865. doi:10.1002/ana.20496
[13]	A. A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, L. Bonaldi, R. Bertorelle, M. Gardiman, C. Ghimenton, P. Iuzzolino, A. Pession, V. Blatt and M. Ermani, “Correlations between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Responses to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study,” Journal of Clinical Oncology, Vol. 24, No. 29, 2006, pp. 4746-4753. doi:10.1200/JCO.2006.06.3891
[14]	J. G. Cairncross, K. Ueki, M. C. Zlatescu, D. K. Lisle, D. M. Finkelstein, R. R. Hammond, J. S. Silver, P. C. Stark, D. R. MacDonald, Y. Ino, D. A. Ramsay and D. N. Louis, “Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients with Anaplastic Oligodendrogliomas,” Journal of the National Cancer Institute, Vol. 90, No. 19, 1998, pp. 1473-1479. doi:10.1093/jnci/90.19.1473
[15]	K. A. Jaeckle, K. V. Baliman, R. D. Rao, R. B. Jenkins and J. C. Buckner, “Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response,” Journal of Clinical Oncology, Vol. 24, No. 8, 2006, pp. 1246-1252. doi:10.1200/JCO.2005.04.9874
[16]	R. B. Jenkins, H. Blair, K. V. Ballman, C. Giannini, R. M. Arusell, M. Law, H. Flynn, S. Passe, S. Felton, P. D. Brown, E. G. Shaw and J. C. Buckner, “A T[1;19][q10;p10] Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma,” Cancer Research, Vol. 66, No. 20, 2006, pp. 9852-9861. doi:10.1158/0008-5472.CAN-06-1796
[17]	N. Levin, I. Lavon, B. Zelikovitsh, D. Fuchs, F. Bokstein, Y. Fellig and T. Siegal, “Progressive Low-Grade Oligodendrogliomas: Response to Temozolomide and Correlation between Genetic Profile and O6-Methylguanine DNA Methyltransferase Protein Expression,” Cancer, Vol. 106, No. 8, 2006, pp. 1759-1765. doi:10.1002/cncr.21809
[18]	G. E. Keles, K. R. Lamborn and M. S. Berger, “Low Grade Hemispheric Gliomas in Adults: A Critical Review of Extent of Resection as a Factor Influencing Outcome,” Journal of Neurosurg, Vol. 95, No. 5, 2001, pp. 735-745. doi:10.3171/jns.2001.95.5.0735
[19]	N. Pouratian, A. Asthagiri, J. Jagannathan, M. E. Shaffrey and D. Schiff, “Surgery Insight: The Role of Surgery in the Management of Low-Grade Gliomas,” Nature Clinical Practice Neurology, Vol. 3, No. 11, 2007, pp 628-639. doi:10.1038/ncpneuro0634
[20]	J. S. Smith, E. F. Chang, K. R. Lamborn, S. M. Chang, M. D. Prados, S. Cha, T. Tihan, S. Vandenberg, M. W. McDermott and M. S. Berger, “Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas,” Journal of Clinical Oncology, Vol. 26, No. 8, 2008, pp. 1338-1345. doi:10.1200/JCO.2007.13.9337
[21]	C. Leighton, B. Fisher, G. Bauman, S. Depiero, L. Stitt, D. MacDonald and G. Cairncross, “Supratentorial Low Grade Glioma in Adults: An Analysis of Prognostic Factors and Timing of Radiation,” Journal of Clinical Oncology, Vol. 15, No. 4, 1997, pp. 1294-1301.
[22]	F. Pignatti, M. van den Bent, D. Curran, C. Debruyne, R. Sylvester, P. Therasse, D. Afra, P. Cornu, M. Bolla, C. Vecht and A. B. Karim, “European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group; Prognostic Factors for Survival in Adult Patients with Cerebral Low-Grade Glioma,” Journal of Clinical Oncology, Vol. 20, No. 8, 2002, pp. 2076-2084. doi:10.1200/JCO.2002.08.121
[23]	E. G. Shaw, S. B. Tatter, G. J. Lesser, T. L. Ellis, C. A. Stanton and V. W. Stieber, “Current Controversies in the Radiotherapeutic Management of Adult Low Grade Glioma,” Seminars in Oncology, Vol. 31, No. 5, 2004, pp. 653-658. doi:10.1053/j.seminoncol.2004.07.007
[24]	S. E. Combs, D. Schulz-Ertner, C. Thilmann, L. Edler and J. Debus, “Fractionated Stereotactic Radiation Therapy in the Management of Primary Oligodendroglioma and Oligoastrocytoma,” International Journal of Radiation Oncology, Vol. 62, No. 3, 2005, pp. 797-802. doi:10.1016/j.ijrobp.2004.11.011
[25]	E. B. Claus, A. Horlacher, L. Hsu, R. B. Schwartz, D. Dello-Iacono, F. Talos, F. A. Jolesz and P. M. Black, “Survival Rates in Patients with Low-Grade Glioma after Intraoperative Magnetic Resonance Image Guidance,” Cancer, Vol. 103, No. 6, 2005, pp. 1227-1233. doi:10.1002/cncr.20867
[26]	M. S. Berger, A. V. Deliganis, J. Dobbins and G. E. Keles, “The Effect of Extent of Resection on Recurrence in Patients with Low Grade Cerebral Hemisphere Gliomas,” Cancer, Vol. 74, No. 6, 1994, pp. 1784-1791. doi:10.1002/1097-0142(19940915)74:6<1784::AID-CNCR2820740622>3.0.CO;2-D
[27]	M. Nakamura, N. Konishi, S. Tsunoda, H. Nakase, T. Tsuzuki, H. Aoki, H. Sakitani, T. Inui and T. Sakaki, “Analysis of Prognostic and Survival Factors Related to Treatment of Low-Grade Astrocytomas in Adults,” Oncology, Vol. 58, No. 2, 2000, pp. 108-116. doi:10.1159/000012087
[28]	P. Celli, I. Nofrone, L. Palma, G. Cantore and A. Fortuna, “Cerebral Oligodendroglioma: Prognostic Factors and Life History,” Neurosurgery, Vol. 35, No. 6, 1994, pp. 1018-1034. doi:10.1227/00006123-199412000-00003
[29]	K. F. Lindegaard, S. J. Mork, G. E. Eide, T. B. Halvorsen, R. Hatlevoll, T. Solgaard, O. Dahl and J. Ganz, “Statistical Analysis of Clinico-Pathological Features, Radiotherapy, and Survival in 170 Cases of Oligodendroglioma,” Journal of Neurosurgery, Vol. 67, No. 2, 1987, pp. 224-230. doi:10.3171/jns.1987.67.2.0224
[30]	E. G. Shaw, B. W. Scheithauer, J. R. O’Fallon, H. D. Tazelaar and D. H. Davis, “Oligodendrogiomas: The Mayo Clinic Experience,” Journal of Neurosurgery, Vol. 76, No. 3, 1992, pp. 428-434. doi:10.3171/jns.1992.76.3.0428
[31]	S. A. Yeh, J. T. Ho, C. C. Lui, Y. J. Huang, C. Y. Hsiung and E. Y. Huang, “Treatment Outcomes and Prognostic Factors of Patients with Supratentorial Low-Grade Oligodendroglioma,” International Journal of Radiation Oncology Biology Physics, Vol. 54, No. 5, 2002, pp. 1405-1409. doi:10.1016/S0360-3016(02)03053-5
[32]	A. B. Karim, B. Maat, R. Hatlevoll, J. Menten, E. H. Rutten, D. G. Thomas, F. Mascarenhas, J. C. Horiot, L. M. Parvinen, M. van Reijn, J. J. Jager, M. G. Fabrini, A. M. van Alphen, H. P. Hamers, L. Gaspar, E. Noordman, M. Pierart and M. van Glabbeke, “A Randomized Trial on Dose-Response in Radiation Therapy of Low-Grade Cerebral Glioma: European Organization for Research and Treatment of Cancer [EORTC] Study 22844,” International Journal of Radiation Oncology, Vol. 36, No. 3 1996, pp. 549-556. doi:10.1016
[33]	E. Shaw, R. Arusell, B. Scheithauer, J. O’Fallon, B. O’Neill, R. Dinapoli, D. Nelson, J. Earle, C. Jones, T. Cascino, D. Nichols, R. Ivnik, R. Hellman, W. Curran and R. Abrams, “Prospective Randomized Trial of Low- Versus High-Dose Radiation Therapy in Adults with Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/ Eastern Cooperative Oncology Group study,” Journal of Clinical Oncology, Vol. 20, No. 9, 2002, pp. 2267-2276. doi:10.1200
[34]	M. J. Van den Bent, D. Afra, O. de Witte, M. Ben Hassel, S. Schraub, K. Hoang-Xuan, P. O. Malmstrom, L. Collette, M. Pierart, R. Mirimanoff and A. B. Karim, “EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council, Long-Term Efficacy of Early Versus Delayed Radiotherapy for Low-Grade Astrocytoma and Oligodendroglioma in Adults: The EORTC 22845 Randomised Trial,” Lancet, Vol. 366, No. 9490, 2005, pp. 985-990. doi:10.1016/S0140-6736(05)67070-5
[35]	J. Knisely, “Early or Delayed Radiotherapy for Low-Grade Glioma?” Lancet, Vol. 6, No. 12, 2005, p. 921.
[36]	Y. Higuchi, Y. Iwadate and A. Yamamura, “Treatment of Low-Grade Oligodendroglial Tumors without Radiotherapy,” Neurology, Vol. 63, No. 12, 2004, pp. 2384-2386.
[37]	O. Surma-aho, M. Niemela, J. Vijkki, M. Kouri, A. Brander, O. Salonen, A. Paetau, M. Kallio, J. Pyykk?nen and J. J??skel?inen, “Adverse Long-Term Effects of Brain Radiotherapy in Adult Low-Grade Glioma Patients,” Neurology, Vol. 56, No. 10, 2001, pp. 1285-1290.
[38]	M. Klein, J. J. Heimans, N. K. Aaronson, P. M. van der Ploeg, J. Grit, M. Muller, T. J. Postma, J. J. Mooij, R. H. Boerman, G. N. Beute, G. J. Ossenkoppele, G. W. van Imhoff, A. W. Dekker, J. Jolles, B. J. Slotman, H. Struikmans and M. J. Taphoorn, “Effect of Radiotherapy and other Treatment-Related Factors on Mid-Term to Long- term Cognitive Sequelae in Low Grade Gliomas: A Comparative Study,” Lancet, Vol. 360, No. 9343, 2002. pp. 1361-1368. doi:10.1016/S0140-6736(02)11398-5
[39]	L. R. Rogers, H. H. Morris and K. Lupica, “Effect of Cranial Irradiation on Seizure Frequency in Adults with Low-Grade Astrocytoma and Medically Intractable Epilepsy,” Neurology, Vol. 43, No. 8, 1993, pp 1599-1601.
[40]	J. D. Olson, E. Riedel and L. M. DeAngelis, “Long-Term Outcome of Low-Grade Oligodendroglioma and Mixed Glioma,” Neurology, Vol. 54, No. 7, 2000, pp. 1442-1448.